Evidence map›Paper›PMID 37047562›Full record

ArticleInternational journal of molecular sciences2023

Crosslinked Chitosan Nanoparticles with Muco-Adhesive Potential for Intranasal Delivery Applications.

Mariacristina Gagliardi, Sara Chiarugi, Chiara De Cesari, Giulia Di Gregorio, Alessandra Diodati, Laura Baroncelli, Marco Cecchini, Ilaria Tonazzini

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Chitosan: Structural and Chemical Modification, Properties, and Application.International journal of molecular sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Mariacristina GagliardiNational Enterprise for nanoScience and nanoTechnology (NEST), Nanoscience Institute-National Research Council (CNR) and Scuola Normale Superiore, Piazza San Silvestro 12, 56127 Pisa, Italy.ORCID 0000-0002-5860-3141
Sara ChiarugiNational Enterprise for nanoScience and nanoTechnology (NEST), Nanoscience Institute-National Research Council (CNR) and Scuola Normale Superiore, Piazza San Silvestro 12, 56127 Pisa, Italy.ORCID 0000-0003-0131-8275
Chiara De CesariNational Enterprise for nanoScience and nanoTechnology (NEST), Nanoscience Institute-National Research Council (CNR) and Scuola Normale Superiore, Piazza San Silvestro 12, 56127 Pisa, Italy.
Giulia Di GregorioNational Enterprise for nanoScience and nanoTechnology (NEST), Nanoscience Institute-National Research Council (CNR) and Scuola Normale Superiore, Piazza San Silvestro 12, 56127 Pisa, Italy.ORCID 0009-0006-5349-814X
Alessandra DiodatiNational Enterprise for nanoScience and nanoTechnology (NEST), Nanoscience Institute-National Research Council (CNR) and Scuola Normale Superiore, Piazza San Silvestro 12, 56127 Pisa, Italy.ORCID 0009-0008-6997-4176
Laura BaroncelliInstitute of Neuroscience, National Research Council (CNR), Via Giuseppe Moruzzi 1, 56124 Pisa, Italy.ORCID 0000-0001-6739-2860
Marco CecchiniNational Enterprise for nanoScience and nanoTechnology (NEST), Nanoscience Institute-National Research Council (CNR) and Scuola Normale Superiore, Piazza San Silvestro 12, 56127 Pisa, Italy.ORCID 0000-0002-9688-2356
Ilaria TonazziniNational Enterprise for nanoScience and nanoTechnology (NEST), Nanoscience Institute-National Research Council (CNR) and Scuola Normale Superiore, Piazza San Silvestro 12, 56127 Pisa, Italy.ORCID 0000-0002-7323-2174
National Enterprise for NanoScience and NanoTechnology · ITFondazione Stella Maris · IT

Funding

Angelman Syndrome Alliance research grant 2021, grant Innovative brain-targeting nano-tools and imaging methods for therapeutic development in Angelman Syndrome (InnovAS)
6 · The paper itself

Abstract

Intranasal drug delivery is convenient and provides a high bioavailability but requires the use of mucoadhesive nanocarriers. Chitosan is a well-established polymer for mucoadhesive applications but can suffer from poor cytocompatibility and stability upon administration. In this work, we present a method to obtain stable and cytocompatible crosslinked chitosan nanoparticles. We used 2,6-pyridinedicarboxylic acid as a biocompatible crosslinker and compared the obtained particles with those prepared by ionotropic gelation using sodium tripolyphosphate. Nanoparticles were tested to evaluate the size and the surface charge, as well as their stability in storage conditions (4 °C), at the nasal cavity temperature (32 °C), and at the body temperature (37 °C). The crosslinked chitosan nanoparticles showed a size around 150 nm and a surface charge of 10.3 mV ± 0.9 mV, both compatible with the intranasal drug administration. Size and surface charge parameters did not significantly vary over time, indicating the good stability of these nanoparticles. We finally tested their cytocompatibility in vitro using SHSY5Y human neuroblastoma and RPMI 2650 human nasal epithelial cells, with positive results. In conclusion, the proposed synthetic system shows an interesting potential as a drug carrier for intranasal delivery.

Indexed as

ChitosanNanoparticlesAdhesivesAdministration, IntranasalDrug CarriersDrug Delivery SystemsHumansParticle SizeAdhesivesChitosanDrug Carrierschitosan nanoparticlesdrug deliveryintranasal administrationmucoadhesion

Identifiers

PMID37047562
PMCPMC10094788
OpenAlexW4362588142

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.